Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 131,000 shares of the stock in a transaction dated Thursday, June 22nd. The shares were purchased at an average price of $6.72 per share, for a total transaction of $880,320.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $20,623,350.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, June 15th, Phillip Md Et Al Frost acquired 200,000 shares of Opko Health stock. The shares were bought at an average price of $6.43 per share, for a total transaction of $1,286,000.00.
  • On Tuesday, June 13th, Phillip Md Et Al Frost acquired 7,200 shares of Opko Health stock. The shares were bought at an average price of $6.51 per share, for a total transaction of $46,872.00.
  • On Monday, June 12th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were bought at an average price of $6.37 per share, for a total transaction of $11,466.00.
  • On Friday, June 9th, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The shares were bought at an average price of $6.39 per share, for a total transaction of $159,750.00.
  • On Wednesday, June 7th, Phillip Md Et Al Frost acquired 55,600 shares of Opko Health stock. The shares were bought at an average price of $6.27 per share, for a total transaction of $348,612.00.
  • On Tuesday, June 6th, Phillip Md Et Al Frost acquired 30,000 shares of Opko Health stock. The shares were bought at an average price of $6.30 per share, for a total transaction of $189,000.00.
  • On Monday, June 5th, Phillip Md Et Al Frost acquired 55,000 shares of Opko Health stock. The shares were bought at an average price of $6.31 per share, for a total transaction of $347,050.00.
  • On Wednesday, May 31st, Phillip Md Et Al Frost acquired 207,700 shares of Opko Health stock. The shares were bought at an average price of $6.11 per share, for a total transaction of $1,269,047.00.
  • On Tuesday, May 30th, Phillip Md Et Al Frost acquired 18,600 shares of Opko Health stock. The shares were bought at an average price of $6.28 per share, for a total transaction of $116,808.00.
  • On Friday, May 26th, Phillip Md Et Al Frost acquired 64,600 shares of Opko Health stock. The shares were bought at an average price of $6.31 per share, for a total transaction of $407,626.00.

Opko Health, Inc. (OPK) traded up 3.44% during midday trading on Friday, hitting $6.92. The company had a trading volume of 705,809 shares. Opko Health, Inc. has a 52 week low of $5.99 and a 52 week high of $12.15. The firm’s 50 day moving average is $6.70 and its 200-day moving average is $8.27. The firm’s market capitalization is $3.87 billion.

Opko Health (NASDAQ:OPK) last released its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.02. The firm had revenue of $296.10 million during the quarter, compared to the consensus estimate of $313.36 million. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The firm’s revenue was up 1.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.02) EPS. On average, equities research analysts expect that Opko Health, Inc. will post ($0.20) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

ILLEGAL ACTIVITY WARNING: “Insider Buying: Opko Health, Inc. (OPK) CEO Buys 131,000 Shares of Stock” was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/06/23/insider-buying-opko-health-inc-opk-ceo-buys-131000-shares-of-stock.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in Opko Health by 11,481.3% in the first quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock worth $181,163,000 after buying an additional 22,449,752 shares in the last quarter. Norges Bank acquired a new stake in Opko Health during the fourth quarter valued at about $30,421,000. State Street Corp raised its stake in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock valued at $87,412,000 after buying an additional 3,138,685 shares during the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its stake in Opko Health by 62.4% in the first quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 5,061,154 shares of the biotechnology company’s stock valued at $40,489,000 after buying an additional 1,944,549 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Opko Health by 4.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company’s stock valued at $210,576,000 after buying an additional 1,112,843 shares during the last quarter. 23.65% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have weighed in on OPK shares. BidaskClub raised Opko Health from a “strong sell” rating to a “sell” rating in a report on Thursday. Jefferies Group LLC reaffirmed a “hold” rating and issued a $8.00 target price on shares of Opko Health in a report on Monday, June 12th. Zacks Investment Research downgraded Opko Health from a “hold” rating to a “sell” rating in a report on Thursday, May 4th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $19.50 target price on shares of Opko Health in a report on Tuesday, June 6th. Finally, Standpoint Research reaffirmed a “buy” rating and issued a $14.00 target price on shares of Opko Health in a report on Sunday, March 5th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $16.58.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.